AstraZeneca-Merck’s Lynparza gets U.S. FDA nod for prostate cancer
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid (Reuters) – The U.S. Food and Drug Administration approved AstraZeneca Plc and Merck & Co Inc’s Lynparza as a treatment for a… Read More »